Ali Behbahani - Dec 13, 2024 Form 4 Insider Report for Black Diamond Therapeutics, Inc. (BDTX)

Role
Director
Signature
/s/ Zachary Bambach, attorney-in-fact
Stock symbol
BDTX
Transactions as of
Dec 13, 2024
Transactions value $
$14,375
Form type
4
Date filed
12/16/2024, 05:09 PM
Previous filing
Oct 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BDTX Common Stock Award $14.4K +5.75K +9.99% $2.50 63.3K Dec 13, 2024 Direct F1, F2
holding BDTX Common Stock 4.45M Dec 13, 2024 See Note 3 F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.
F2 The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 12, 2024.
F3 The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. ("NEA 16"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest.